Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 06 September 2013 | By Alexander Gaffney, RAC,
The US Food and Drug Administration (FDA) has announced it plans to hold a joint workshop with the American Academy of Ophthalmology (AAO) to address challenges that affect the regulatory assessment of innovative intraocular lenses (IOLs).
IOLs are-as their name implies-lenses that are physically implanted into the eye, most often to treat medical conditions like cataracts which otherwise disrupt the body's own crystalline lens.
FDA's Federal Register notice on the meeting explains that surgical procedures to implant IOLs are the most commonly performed elective procedures in the US, with more than three million patients receiving an IOL since they were introduced to the market.
However, regulators say both they and industry are running into a problem. Over the last 20 years, IOL technology has evolved, outgrowing the traditional clinical trial endpoints once used to evaluate the products.
"As IOL technology evolves, some endpoints for the evaluation of the technology are also evolving," FDA wrote in its notice. "Endpoints and strategies for assessing the relative safety and effectiveness of these innovative lens designs are in various stages of development."
And that, FDA said, is where an upcoming workshop is set to make an impact. Regulators and industry are set to come together on 11 October 2013 to discuss novel trial endpoints, as well as the benefits and challenges inherent in using those endpoints.
In addition, endpoints will also be "prioritized for further discussion, development and validation."
"By bringing together all of the relevant stakeholders, which include clinicians, researchers, industry representatives, and regulators, to this workshop, we hope to facilitate the improvement of regulatory science in this rapidly evolving product area," FDA wrote.
The Federal Register notice adds that four general topics are set to be discussed at the meeting:
Additional documentation released by AAO notes that the group is interested in modifying the ISO 11979-7 standard (Ophthalmic Implants - Intraocular Lenses - Part 7: Clinical Investigations), particularly with respect to adverse event reporting.
At present, six FDA participants are scheduled to attend the meeting:
Cost of attendance will be between $250 and $450, with FDA providing a free transcript of the meeting online within 45 days of the workshop's conclusion.
Federal Register Notice
AAO Meeting Details
Tags: Meeting, workshop
Regulatory Focus newsletters
All the biggest regulatory news and happenings.